Japan’s Takeda forecasts $1.76b operating loss on Shire acquisition

Shire logos sit on the boxes of Elvanse 50mg tablets, produced by Shire Plc, left, and Mezavant XL 1200mg tablets, produced by Shire Plc, in this arranged photograph taken at a pharmacy in London, U.K., on Tuesday, July 8, 2014. Photographer: Bloomberg/Bloomberg

Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.